1 |
Stevens R J Kothari V Adler A I Stratton I M United Kingdom Prospective Diabetes Study(UKPDS) Group. TheUKPDS risk engine: a model for the risk of coronary heart diseasein Type II diabetes (UKPDS 56)Clin Sci(Lond) 2001 101(6)671679
|
2 |
Lu Z L Du B M Chen Z H Wu Y F Yu X H Zhao Y C (representthe effect of Xuezhikang regulatingthe blood fat to China Coronary Secondary Prevention Study Collaborativegroup). China Coronary Secondary Prevention Study (CCSPS)-analysisresult of patients with type 2 diabetes.Zhonghua Xin Xue Guan Bing Za Zhi 2005 33(2)10671070(in Chinese)
|
3 |
Zhang M L Duan Z W Xie S M The Xuezhikang activecomponent studyZhongguo Xin Yao Za Zhi 1990 43(12)1624(in Chinese)
|
4 |
Chen Y C Zhao S P Liu L Liu M H Li Y L Influence of lipid-modulating therapy onhigh-fat diet induce endothelial dysfunction in patients with coronaryheart diseaseZhonghua Xin Xue Guan BingZa Zhi 2004 32(2)114117(in Chinese)
|
5 |
Xu B P Chen Y L Lu X The effect of Xuezhikang on oxidation of low density lipoproteins in virtoZhonghua Nei Ke Za Zhi 1999 38(8)520522(in Chinese)
|
6 |
Huang Y Chen Y Z Shi R F Deng G L Inhibitingeffects of Xuezhikang on Monocytesadhesion in the patients with hypercholesterolemiaZhongguo Dong Mai Ying Hua Za Zhi 2002 10(1)5355(in Chinese)
|
7 |
Wu Y J Yu H Qin X W Wang X Y Sun Y H Chen J L Kou W R Lu Z L Small dense low-density lipoprotein in different type ofhyperlipidimia: Effect of lipid-lowering therapyZhongguo Xun Huan Za Zhi 2002 17(6)431433(in Chinese)
|
8 |
Zhang P H Li P Han X N Zhang X C Chen L Y Inhibitory effect of Xuezhikang on matrix metalloproteinase-2 secreted by macrophageZhonghua Xin Xue Guan Bing Za Zhi 2001 29(8)497499(in Chinese)
|
9 |
Zhao S P Liu L Cheng Y C Li Y L Effect of Xuezhikang, a cholestin extract, on reflectingpostprandial triglyceridemia after a high-fat meal in patients withcoronary heart diseaseAtherosclerosis 2003 168(2)375380. doi:10.1016/S0021‐9150(03)00142‐4
|
10 |
Zhao S P Lu Z L Du B M Chen Z Wu Y F Yu X H Zhao Y C Liu L Ye H J Wu Z H Xuezhikang, an extract of cholestin, reduces cardiovascular events in type2 diabetes patients with coronary heart disease: Subgroup analysisof patients with type 2 diabetes from China Coronary Secondary PreventionStudy (CCSPS)J Cardiovasc Pharmacol 2007 49(2)14. doi:10.1097/FJC.0b013e31802d3a58
|
11 |
Laakso M Diabetesand cardiovascular disease in type 2 diabetes: Challenge for treatmentand preventionJ Intern Med 2001 249(3)225235. doi:10.1046/j.1365‐2796.2001.00789.x
|